NCT01464944 - Placebo and Active Controlled Study to Compare the Antipyretic Efficacy of Aspirin® in Patients With Acute Febrile Upper Respiratory Tract Infections Suspected to be of Viral Origin | Biotech Hunter

Enrollment

392

Participants

Timeline

Start Date

November 30, 2003

Study Completion Date

April 30, 2004

Conditions

Respiratory Tract InfectionsFever

Interventions

DRUG

Acetylsalicylic acid (Aspirin, BAYE4465)

Acetylsalicylic acid 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Acetylsalicylic acid, and 2 Placebo tablets of Paracetamol

DRUG

Acetylsalicylic acid (Aspirin, BAYE4465)

Acetylsalicylic acid 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Paracetamol

DRUG

Paracetamol

Paracetamol 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Paracetamol, and 2 Placebo tablets of Acetylsalicylic Acid

DRUG

Paracetamol

Paracetamol 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Acetylsalicylic Acid

DRUG

Placebo

2 Placebo tablets of Acetylsalicylic Acid, and 2 Placebo tablets of Paracetamol, orally, single dose

Trial Locations (9)

91011

Luhansk

105064

Moscow

107996

Moscow

109386

Moscow

125183

Moscow

127015

Moscow

127299

Moscow

02232

Kiev

03049

Kiev